Evidence map›Paper›PMID 36301972›Full record

ArticlePloS one2022

Annona muricata L. peel extract inhibits carbohydrate metabolizing enzymes and reduces pancreatic β-cells, inflammation, and apoptosis via upregulation of PI3K/AKT genes.

Oluwafemi Adeleke Ojo, Susan Grant, Jennifer Chidubem Amanze, Abosede Itunuoluwa Oni, Adebola Busola Ojo, Tobiloba Christiana Elebiyo, Tajudeen Olabisi Obafemi, Damilare Iyinkristi Ayokunle, Akingbolabo Daniel Ogunlakin

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Leveraging Underutilized Sri Lankan Fruits in the Fight against Autoimmune Disorders.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2025
    Review
  4. Review
  5. Soursop (Foods (Basel, Switzerland) · 2023
    Review
  6. Review
  7. Role of ceramides in diabetic foot ulcers (Review).International journal of molecular medicine · 2023
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Oluwafemi Adeleke OjoDepartment of Biochemistry, Landmark University, Omu-Aran, Nigeria.ORCID 0000-0001-9331-396X
Susan GrantDepartment of Biochemistry, Landmark University, Omu-Aran, Nigeria.
Jennifer Chidubem AmanzeDepartment of Biochemistry, Landmark University, Omu-Aran, Nigeria.
Abosede Itunuoluwa OniDepartment of Biochemistry, Landmark University, Omu-Aran, Nigeria.
Adebola Busola OjoDepartment of Biochemistry, Ekiti State University, Ado-Ekiti, Nigeria.
Tobiloba Christiana ElebiyoDepartment of Biochemistry, Landmark University, Omu-Aran, Nigeria.
Tajudeen Olabisi ObafemiDepartment of Biochemistry, Afe Babalola University, Ado-Ekiti, Nigeria.
Damilare Iyinkristi AyokunleDepartment of Pure and Applied Biology, Bowen University, Iwo, Nigeria.ORCID 0000-0003-1632-3528
Akingbolabo Daniel OgunlakinDepartment of Biochemistry, Bowen University, Iwo, Nigeria.
Landmark University · NGBowen University · NGAfe Babalola University · NGEkiti State University · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveAnnona muricata L. peel has been recognized for many ethnobotanical uses, including diabetes management. However, limited detailed scientific information about its mechanism of antidiabetic activity exists. The objective of this study was to evaluate the anti-diabetic properties of an aqueous extract of A. muricata peel (AEAMP) and its mechanism of action on alloxan-induced diabetic rats.

methodsIn vitro antidiabetic assays, such as α-amylase and α-glucosidase were analyzed on AEAMP. Alloxan monohydrate (150 mg/kg b.w) was used to induce diabetes in the rats. 150 mg/kg b.w positive control group doses of 6.67, 13.53, and 27.06 mg/kg were administered to 3 groups for twenty-one days. The positive control group was administered 30 mg/kg of metformin. The negative and normal control groups were administered distilled water. The fasting blood glucose, serum insulin, lipid profile, inflammatory cytokines, antioxidant markers, carbohydrate metabolizing enzymes, and liver glycogen were analyzed as well as PI3K/AKT and apoptotic markers PCNA and Bcl2 by RT-PCR.

resultsAEAMP inhibited α-amylase and α-glucosidase enzymes more effectively than acarbose. AEAMP reduced FBG levels, HOMA-IR, G6P, F-1,6-BP, MDA, TG, TC, AI, CRI, IL-6, TNF-α, and NF-κB in diabetic rats. Furthermore, in diabetic rats, AEAMP improved serum insulin levels, HOMA-β, hexokinase, CAT, GST, and HDL-c. Liver PI3K, liver PCNA and pancreas PCNA were not significantly different in untreated diabetic rats when compared to normal rats suggesting alloxan induction of diabetes did not downregulate the mRNA expression of these genes. AEAMP significantly up-regulated expression of AKT and Bcl2 in the liver and pancreatic tissue. It is interesting that luteolin and resorcinol were among the constituents of AEAMP.

conclusionsAEAMP can improve β-cell dysfunction by upregulating liver AKT and pancreatic PI3K and AKT genes, inhibiting carbohydrate metabolizing enzymes and preventing apoptosis by upregulating liver and pancreatic Bcl2. However, the potential limitation of this study is the unavailability of equipment and techniques for collecting more data for the study.

Indexed as

AnnonaDiabetes Mellitus, ExperimentalHypoglycemic AgentsPlant ExtractsAlloxanalpha-Amylasesalpha-GlucosidasesAnimalsApoptosisBlood GlucoseInflammationInsulinsPhosphatidylinositol 3-KinasesProliferating Cell Nuclear AntigenProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-bcl-2Alloxanalpha-Amylasesalpha-GlucosidasesBlood GlucoseHypoglycemic AgentsInsulinsPhosphatidylinositol 3-KinasesPlant ExtractsProliferating Cell Nuclear AntigenProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-bcl-2

Identifiers

PMID36301972
PMCPMC9612462
OpenAlexW4307441275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.